ติดตาม
David M Hyman
David M Hyman
Loxo Oncology, Eli Lilly
ยืนยันอีเมลแล้วที่ loxooncology.com - หน้าแรก
ชื่อ
อ้างโดย
อ้างโดย
ปี
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
32392017
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
27682018
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
23682017
A view on drug resistance in cancer
N Vasan, J Baselga, DM Hyman
Nature 575 (7782), 299-309, 2019
22472019
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
19892015
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
14942017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
10992018
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ...
The Lancet Oncology 21 (4), 531-540, 2020
9362020
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
9182018
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
7782018
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ...
Cell stem cell 21 (3), 374-382. e4, 2017
7782017
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
7582018
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
6422017
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
EL Diamond, L Dagna, DM Hyman, G Cavalli, F Janku, J Estrada-Veras, ...
Blood, The Journal of the American Society of Hematology 124 (4), 483-492, 2014
6312014
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ...
Nature medicine 25 (12), 1928-1937, 2019
6222019
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of clinical oncology 37 (4), 286-295, 2019
5912019
Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ...
JCO precision oncology 1, 1-16, 2017
5832017
Genome doubling shapes the evolution and prognosis of advanced cancers
CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ...
Nature genetics 50 (8), 1189-1195, 2018
5742018
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ...
Nature genetics 52 (11), 1219-1226, 2020
5632020
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532-2537, 2018
5502018
ระบบไม่สามารถดำเนินการได้ในขณะนี้ โปรดลองใหม่อีกครั้งในภายหลัง
บทความ 1–20